about
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United StatesReview of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan AfricaHIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA PanelHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessRoutine HIV screening in France: clinical impact and cost-effectivenessCost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisWHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothersWhat will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysisDrug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South AfricaThe cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysisPoint-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysisIntegrating social contact and environmental data in evaluating tuberculosis transmission in a South African townshipHIV self-testing and the missing linkage.Does modality of survey administration impact data quality: audio computer assisted self interview (ACASI) versus self-administered pen and paper?The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa.Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survivalEarly infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions.Emergency provider attitudes and barriers to universal HIV testing in the emergency departmentGlobal health training in US graduate psychiatric educationTest and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DCPrevalence and correlates of clinically significant depressive symptoms in an urban hospital emergency department.Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency departmentManaging the demand for global health education.Estimation of the prevalence of undiagnosed and diagnosed HIV in an urban emergency departmentQuantification of shared air: a social and environmental determinant of airborne disease transmission.Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.Screening for acute HIV infection in South Africa: finding acute and chronic disease.Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South AfricaRoutine HIV testing in adolescents and young adults presenting to an outpatient clinic in Durban, South AfricaNatural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic reviewHIV cure strategies: how good must they be to improve on current antiretroviral therapy?The survival benefits of AIDS treatment in the United States.Missed opportunities: refusal to confirm reactive rapid HIV tests in the emergency department
P50
Q22242768-2804BB00-2F88-4E3A-91B6-B1F667BAA092Q22242974-DEF5577B-A677-4A44-B439-CB708C27D26EQ28244216-E50E3663-9BCD-49B6-948B-C3B694E509DBQ28474086-5638A0FE-0312-4DB9-AA8B-540134236839Q28475837-52659C86-A593-4DB6-99F4-47554E95F846Q28476337-547A705C-E909-4FAA-9D53-5493DFA924B4Q28476684-4FE94718-71D1-4B78-99DA-5E4BA48BB3B5Q28478406-A5739E8D-7951-4617-A028-C575AAF95416Q28478769-33460598-E7A5-497B-BF2F-896BC02A511AQ28482343-89C1DE6C-D266-4574-99D9-783EE70FFFE2Q28483035-3D47DA02-BDE7-4AB9-AE38-E34BA37D8A43Q28543954-5CE87322-9FB1-4EA5-AC89-7565BC23D84FQ30773592-ACE80C40-0496-4801-831C-C9B818959658Q31032212-F18B2038-2BA8-43BC-A47B-CA5DD26D0CF3Q33525582-CA3A5B8E-B296-42E6-A021-861DEFD893F0Q33537984-5E729196-24A1-46A2-B3E5-B346C2C7EAD4Q33670446-624B8FE9-8E51-465D-8B31-39D07852CD5AQ33700455-D184033D-6760-4C2A-8D70-C3A12326F6BEQ33893797-6926BE90-2C60-4AC7-87C9-F908D1C81065Q33897042-300158F5-D95F-4EAE-86A9-83AED236CD1FQ33902803-6D6BA824-F254-40DB-BF7E-47842386A84FQ33907111-BC56C372-A040-4931-9BA3-B176C4220238Q33927787-8239F665-1843-4FD6-99C2-906FB9A0F597Q33953175-AEA948CD-E59B-4A77-8297-1C0849611D87Q34005333-BEAA71D3-8E0C-486D-9932-7FE21774E0BFQ34024079-904E7B6E-DF9D-4F73-8503-AB6201D4E833Q34055648-7C75C301-FE05-40A8-903E-993611E6D475Q34075378-D00533E7-BAD2-451A-8FB1-27D8F6224766Q34081738-698FA033-B823-47A6-B504-A2F06BCC7418Q34122533-03FD155B-AA61-4568-8CE3-7DBFF91CBBFFQ34153838-B449ED93-BB72-416B-9AB8-A7CA5636CB1BQ34195493-312D7FF0-6B7E-48CB-B749-B9998488CA08Q34268037-CE251FC6-634E-45CF-B792-170165EBCF7FQ34393599-5DED4313-CEB0-412E-B847-A5CAC302616CQ34423942-C18AFA39-2F2D-4B22-AF73-82AD4A969CF2Q34429246-084ECEB2-ACAA-45BB-AFC7-D709ADF7202EQ34503284-88093CE5-A919-4716-9363-CAF2C75F4C5CQ34514601-9F0F16B2-F9AE-4016-B2C0-43505349EB13Q34533291-C421002B-4274-4A52-BBD9-3CEA43AE6F62Q34545039-91F2FF90-7C95-41FC-BCAF-D3CA80821C2D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rochelle P. Walensky
@ast
Rochelle P. Walensky
@en
Rochelle P. Walensky
@es
Rochelle P. Walensky
@nl
Rochelle P. Walensky
@sl
type
label
Rochelle P. Walensky
@ast
Rochelle P. Walensky
@en
Rochelle P. Walensky
@es
Rochelle P. Walensky
@nl
Rochelle P. Walensky
@sl
prefLabel
Rochelle P. Walensky
@ast
Rochelle P. Walensky
@en
Rochelle P. Walensky
@es
Rochelle P. Walensky
@nl
Rochelle P. Walensky
@sl
P108
P106
P1153
6602540593
P21
P31
P496
0000-0002-8795-379X